|Day Low/High||0.01 / 0.01|
|52 Wk Low/High||0.00 / 0.01|
The company lost its bid for Inamed and posted a weak quarter, but its deal for Reloxin's a real coup.
Two readers figured out the options trading around this deal.
We've got 45 minutes to answer three questions about options trading around this deal.
Cramer says the fat-fighting craze offers several good stock plays.
The exchange offer was scheduled to expire Tuesday but will now end Feb. 22.
The deal is still waiting for clearance from the U.S. Federal Trade Commission.
Cramer says there's money to be made from the boomer generation's quest for artificial youth .
Medicis withdrew its agreement to buy Inamed and received a $90 million break-up fee.
However, the company's directors say Allergan's offer is superior to the proposal from Medicis.
Medtronic and Nastech are among a host of players aiming to cut obesity rates.
If Inamed goes with Allergan, he says his firm won't rethink its business strategy.
We're close to a more lasting rally, but be aware of recent technical damage.
The company could soon join rival Mentor in selling silicone gel breast implants.
The Arms Index numbers still indicate that a short-term rally -- only for the nimble -- is almost upon us.
Neither the agency nor the company would provide details on the conditions imposed by the FDA.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.